A prospective Longitudinal trial of the effect of Atomoxetine on cognitive, educational, behavioural, social and emotional wellbeing in students with Attention Deficit Hyperactivity Disorder

Completed

• Conditions: Attention Deficit Hyperactivity Disorder; Mental and Behavioural Disorders; Behavioural and emotional disorders

• Registration Number: ISRCTN05214203
• Lead Sponsor: Australian Research Council (Australia)

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Study Start: 2006-11-20
• Last Update Posted: 13 January 2015

Recruitment & Eligibility

• Status: Completed
• Sex: All
• Target Recruitment: 144

Inclusion Criteria

1. Boys and girls aged seven to 15 years
2. Meet the Diagnostic and Statistical Manual of Mental Disorders - Fourth Edition (DSM-IV) criteria for ADHD, as determined by the referring paediatrician or child psychiatrist
3. Participants are naive to atomoxetine medication

Exclusion Criteria

1. A history of bipolar or psychotic disorder
2. Tourette?s syndrome
3. Substance abuse
4. Serious medical illness
5. Intellectual disability (Intelligence Quotient [IQ] less than 70)
6. Pregnancy
7. Non compliance with research protocol

Study & Design

• Study Type: Interventional
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
1. Cognitive functioning, working memory, verbal ability and cognitive efficiency<br>2. Executive functioning (teacher and parent ratings)<br>3. Educational achievement

Secondary Outcome Measures

Name	Time	Method
1. Depression (child, parent, teacher ratings)<br>2. Anxiety (child and parent ratings)<br>3. Social skills (teacher and parent ratings)<br>4. Perceptions of learning environment (child ratings)